Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2005 3
2007 2
2008 5
2009 5
2010 7
2011 7
2012 6
2013 5
2014 2
2015 11
2016 6
2017 5
2018 5
2019 11
2020 8
2021 6
2022 12
2023 6
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

98 results

Results by year

Filters applied: . Clear all
Page 1
Pattern and risk factors of isolated local relapse among women with hormone receptor-positive and HER2-negative breast cancer and lymph node involvement: 10-year follow-up analysis of the PACS 01 and PACS 04 trials.
Rassy E, Filleron T, Viansone A, Lacroix-Triki M, Rivera S, Desmoulins I, Serin D, Canon JL, Campone M, Gonçalves A, Levy C, Cottu P, Petit T, Eymard JC, Debled M, Bachelot T, Dalenc F, Roca L, Lemonnier J, Delaloge S, Pistilli B. Rassy E, et al. Among authors: debled m. Breast Cancer Res Treat. 2023 Jun;199(2):371-379. doi: 10.1007/s10549-023-06912-4. Epub 2023 Mar 29. Breast Cancer Res Treat. 2023. PMID: 36988749
Long-Term Results with Everolimus in Advanced Hormone Receptor Positive Breast Cancer in a Multicenter National Real-World Observational Study.
François-Martin H, Lardy-Cléaud A, Pistilli B, Levy C, Diéras V, Frenel JS, Guiu S, Mouret-Reynier MA, Mailliez A, Eymard JC, Petit T, Ung M, Desmoulins I, Augereau P, Bachelot T, Uwer L, Debled M, Ferrero JM, Clatot F, Goncalves A, Chevrot M, Chabaud S, Cottu P. François-Martin H, et al. Among authors: debled m. Cancers (Basel). 2023 Feb 13;15(4):1191. doi: 10.3390/cancers15041191. Cancers (Basel). 2023. PMID: 36831532 Free PMC article.
Clinical outcome of patients with isolated central nervous system progression on first-line pertuzumab and trastuzumab treatment for HER2-positive metastatic breast cancer in a real-life cohort.
Collet L, Eberst L, Ludovic G, Debled M, Hrab L, Mouret-Reynier MA, Desmoulins I, Goncalves A, Campone M, Ferrero JM, Brain E, Uwer L, Eymard JC, Dieras V, Simon G, Leheurteur M, Dalenc F, Vanlemmens L, Darlix A, Arnedos M, Bachelot T. Collet L, et al. Among authors: debled m. Breast Cancer. 2023 Mar;30(2):329-341. doi: 10.1007/s12282-022-01427-0. Epub 2023 Jan 11. Breast Cancer. 2023. PMID: 36630013
Association of Endocrine Therapy for HR+/ERBB2+ Metastatic Breast Cancer With Survival Outcomes.
Carausu M, Carton M, Diéras V, Petit T, Guiu S, Gonçalves A, Augereau P, Ferrero JM, Levy C, Ung M, Desmoulins I, Debled M, Bachelot T, Pistilli B, Frenel JS, Mailliez A, Chevrot M, Cabel L. Carausu M, et al. Among authors: debled m. JAMA Netw Open. 2022 Dec 1;5(12):e2247154. doi: 10.1001/jamanetworkopen.2022.47154. JAMA Netw Open. 2022. PMID: 36520434 Free PMC article.
Survival outcomes of metastatic breast cancer patients by germline BRCA1/2 status in a large multicenter real-world database.
Mailliez A, D'Hondt V, Lusque A, Caron O, Cabel L, Goncalves A, Debled M, Gladieff L, Ferrero JM, Petit T, Mouret-Reynier MA, Eymard JC, Levy C, Uwer L, Leheurteur M, Desmoulins I, Bachelot T, Frenel JS, de la Motte Rouge T, Simon G, Jacot W, Delaloge S. Mailliez A, et al. Among authors: debled m. Int J Cancer. 2023 Mar 1;152(5):921-931. doi: 10.1002/ijc.34304. Epub 2022 Oct 8. Int J Cancer. 2023. PMID: 36161271 Free PMC article.
Efficacy of taxanes rechallenge in first-line treatment of early metastatic relapse of patients with HER2-negative breast cancer previously treated with a (neo)adjuvant taxanes regimen: A multicentre retrospective observational study.
Vasseur A, Carton M, Guiu S, Augereau P, Uwer L, Mouret-Reynier MA, Levy C, Eymard JC, Ferrero JM, Leheurteur M, Goncalves A, Robert M, De La Motte Rouge T, Bachelot T, Petit T, Debled M, Grinda T, Desmoulins I, Vanlemmens L, Nicolaï V, Simon G, Cabel L. Vasseur A, et al. Among authors: debled m. Breast. 2022 Oct;65:136-144. doi: 10.1016/j.breast.2022.07.014. Epub 2022 Aug 4. Breast. 2022. PMID: 35944353 Free PMC article.
Everolimus Added to Adjuvant Endocrine Therapy in Patients With High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer.
Bachelot T, Cottu P, Chabaud S, Dalenc F, Allouache D, Delaloge S, Jacquin JP, Grenier J, Venat Bouvet L, Jegannathen A, Campone M, Del Piano F, Debled M, Hardy-Bessard AC, Giacchetti S, Mouret-Reynier MA, Barthelemy P, Kaluzinski L, Mailliez A, Legouffe E, Sephton M, Bliss J, Canon JL, Penault-Llorca F, Lemonnier J, Cameron D, Andre F. Bachelot T, et al. Among authors: debled m. J Clin Oncol. 2022 Nov 10;40(32):3699-3708. doi: 10.1200/JCO.21.02179. Epub 2022 May 23. J Clin Oncol. 2022. PMID: 35605174 Clinical Trial.
Neoadjuvant chemotherapy and radiotherapy for locally advanced breast cancer: Safety and efficacy of reverse sequence compared to standard technique?
Maire M, Debled M, Petit A, Fournier M, Macgrogan G, Quenel-Thueux N, Charitansky H, Mathoulin-Pelissier S, Bonnefoi H, Tunon de Lara C. Maire M, et al. Among authors: debled m. Eur J Surg Oncol. 2022 Aug;48(8):1699-1705. doi: 10.1016/j.ejso.2022.04.022. Epub 2022 Apr 29. Eur J Surg Oncol. 2022. PMID: 35523623
98 results